Medikamente in der schwangerschaft

2Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Exaggerated caution or even deferment in the treatment of chronically ill mothers-to-be, for example, in the case of epilepsy, hypertension or bronchial asthma, may result in a dramatic worsening of the underlying disease and thus may threaten the further development of the fetus. On the other hand, an inadequate knowledge of the true risks of pharmacological treatment already applied in the early stages of pregnancy, leads to numerous abortions that are inappropriately indicated. As a basic rule, when planning pharmacological treatment in a pregnant woman, well tried and tested substances should be given preference over new drugs. If a pregnant woman has been exposed to an insufficiently tested substance as a result of ignorance of her pregnancy, recognized centers with appropriate data banks (www.reprotox.de) should be consulted.

Cite

CITATION STYLE

APA

Paulus, W. (2005, April 21). Medikamente in der schwangerschaft. MMW-Fortschritte Der Medizin. https://doi.org/10.1007/978-3-662-39609-4_102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free